Navigation Links
Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
Date:5/28/2013

LAVAL, Quebec, May 28, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has received a Complete Response Letter (CRL)  from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for efinaconazole for the treatment of onychomycosis.  A CRL is issued by the FDA's Center for Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form.  The questions raised by the FDA pertain only to Chemistry, Manufacturing and Controls (CMC) related areas of the container closure apparatus. As no efficacy or safety issues were raised by the FDA, Valeant believes that these items can be addressed and is working for a timely response to the FDA as soon as possible.  Valeant remains committed to bringing efinaconazole to market as a potential new treatment for onychomycosis. 

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding our expectation to address matters raised in the Complete Response Letter, the approval of efinaconazole and the timing of any such approval.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target", or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the uncertainty of approval of product candidates and the risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO )


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Noom, Inc., ... it will charge enterprise customers only when their members ... the health and wellness sector, which typically charges for ... - http://photos.prnewswire.com/prnh/20161207/446824LOGO ... the power of technology with the empathy of live ...
(Date:12/8/2016)... BRAINTREE, Mass. , Dec. 8, 2016  Haemonetics Corporation ... to NextGen DMS (Donor Management System), an innovative software suite ... operations. The launch of NextGen DMS 4 ... focus including: reducing the cost per liter of plasma collected, ... and improve plasma center operations. ...
(Date:12/8/2016)... -- Stock-Callers.com revisits the Drug Manufacturers industry, ... of pharmaceutical drug products. Companies in this space can ... these firms typically have dividend yields that are higher ... review this morning are: Novo Nordisk A/S (NYSE: ... SGYP ), Pernix Therapeutics Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally owned ... clients in the northern Alabama and Georgia regions, is embarking on a charity ... Works has built a network of support and education facilities to develop and ...
(Date:12/7/2016)... ... 07, 2016 , ... "Today, MHA and mental health advocates ... systems reform legislation in more than fifty years. We applaud the bipartisan action ... elected officials to improving mental health services and supports in our nation. , ...
Breaking Medicine News(10 mins):